Last updated: June 8, 2022
Sponsor: Stony Brook University
Overall Status: Completed
Phase
N/A
Condition
Blood Clots
Thrombocytopenic
Thrombosis
Treatment
N/AClinical Study ID
NCT05272475
IRB2022-00036
Ages 18-75 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Able to provide informed written consent
- Able to withhold use of other chamomile products (teas, lotions, supplements,extracts); will only use study-supplied chamomile products for duration of study
- Able to withhold intake of solid food at least 6 hours before intake of the chamomilepreparation
- Able to withhold intake of clear liquids at least 2 hours before intake of thechamomile preparation
Exclusion
Exclusion Criteria:
- Past medical/family history of bleeding/thrombotic disorders (e.g. hemophilia,von-Willebrand disease)
- Chronic medications known to affect hemostasis (anticoagulants, antiplatelet agents,SSRIs, herbal/complementary medicine agents)
- Three or more alcoholic drinks daily
- Sedentary status/ restricted mobility
- Active smoker or quit smoking within one week of study period
- Females who are pregnant, breast-feeding, or lactating
- History of estrogen-dependent condition such as uterine fibroids, breast cancer,uterine cancer, or ovarian cancer
- Scheduled surgical procedure during study period
- Hospitalized patients
- Underweight (BMI < 18 kg/m2) or history of malnourishment
- Active symptoms of a respiratory, dermatologic, urinary, or gastrointestinal infection
- Diagnosed allergy to chamomile
- Severe allergy to ragweed
- Physical inability to consume chamomile tea according to the study dosing schedule
- Prescription usage of an anticoagulant agent such as warfarin, anti-Xa inhibitor, orother novel oral anticoagulants
- ADP antagonist use, including clopidogrel, prasugrel, and ticagrelor
- GPIIb/IIIa inhibitor use, including ticlopidine, eptifibatide
- More than weekly NSAID use (e.g. aspirin, ibuprofen, naproxen)
- Diagnosis of a bleeding-diathesis disorder
- Diagnosis of a hypercoagulable state
- History of elevated INR or other abnormal bleeding study (PT, aPTT, thrombin time,reptilase time, above the upper limit of normal for Stony Brook Hospital ReferenceRange) while not taking anticoagulants or herbal supplements listed below
- Active intake of the following herbal supplements at time of study enrollment that mayalter baseline coagulation function including:
- Ginger
- Garlic
- Gingko
- Ginseng
- Fish oil
- Black Cohosh
- Feverfew
- Valerian
- Coenzyme Q10
- Goldenseal
- St. John Wort
- Active intake of chamomile extracts or teas at time of study enrollment
- Inability to discontinue the aforementioned herbal supplements more than 14 daysbefore enrollment into the study
- Significant fear of needles or fainting blood draws
- Actively taking cyclosporine
- Patient refusal to participate in study for the allotted study period
Study Design
Total Participants: 8
Study Start date:
March 16, 2022
Estimated Completion Date:
May 12, 2022
Study Description
Connect with a study center
Stony Brook University Hospital
Stony Brook, New York 11794
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.